Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.-MedSci.cn

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

Brahmer, JR; Johnson, ML; Dols, MC; Ramirez, SV; Coves, J; Sukari, A; Awad, MM; Salgia, R; Papadimitrakopoulou, V; Rajan, A; Allred, AJ; Wade, M; Mason, G; Zudaire, E; Knoblauch, RE; Stone, NL; Lorenzi, MV; Hassan, R

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务